GlassScriptPhysician profile
Dylan W Hance
NPI 1972363471
$2,548.46
in general payments reported to CMS, 2019-2025
9 companies · $459 in 2025
The $459 reported for 2025 was more than what 75% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,090 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,301 · Travel and Lodging: $1,247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,301.02 |
| Travel and Lodging | $1,247.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,741.66 | 2024 | Rocklatan, Simbrinza, Rhopressa |
| Harrow Eye, LLC | $241.62 | 2024-2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $172.31 | 2024 | Xdemvy |
| New World Medical,INC. | $103.36 | 2025 | Ahmed Glaucoma Valve, Streamline, Clearpath |
| Dompe US, INC. | $102.33 | 2024-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $96.69 | 2024 | Xiidra, Miebo |
| Mallinckrodt Hospital Products INC. | $36.62 | 2025 | Acthar |
| Ani Pharmaceuticals, INC. | $31.23 | 2025 | Purified Cortrophin Gel |
| Johnson & Johnson Surgical Vision, INC. | $22.64 | 2025 | Tecnis Iol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dylan Hance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.